US5367057A
(en)
*
|
1991-04-02 |
1994-11-22 |
The Trustees Of Princeton University |
Tyrosine kinase receptor flk-2 and fragments thereof
|
US6448077B1
(en)
*
|
1994-02-10 |
2002-09-10 |
Imclone Systems, Inc. |
Chimeric and humanized monoclonal antibodies specific to VEGF receptors
|
US20030108545A1
(en)
*
|
1994-02-10 |
2003-06-12 |
Patricia Rockwell |
Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
|
US6136311A
(en)
|
1996-05-06 |
2000-10-24 |
Cornell Research Foundation, Inc. |
Treatment and diagnosis of cancer
|
AU2469299A
(en)
*
|
1998-01-23 |
1999-08-09 |
Cornell Research Foundation Inc. |
Purified populations of stem cells
|
US6537520B1
(en)
*
|
1998-03-31 |
2003-03-25 |
Bristol-Myers Squibb Pharma Company |
Pharmaceuticals for the imaging of angiogenic disorders
|
US20030176663A1
(en)
*
|
1998-05-11 |
2003-09-18 |
Eidgenossische Technische Hochscule |
Specific binding molecules for scintigraphy
|
AU757698C
(en)
*
|
1998-06-01 |
2004-04-08 |
Agensys, Inc. |
Novel serpentine transmembrane antigens expressed in human cancers and uses thereof
|
US6962702B2
(en)
|
1998-06-22 |
2005-11-08 |
Immunomedics Inc. |
Production and use of novel peptide-based agents for use with bi-specific antibodies
|
CA2344653A1
(en)
*
|
1998-09-29 |
2000-04-06 |
Gamida Cell Ltd. |
Methods of controlling proliferation and differentiation of stem and progenitor cells
|
ATE322909T1
(de)
*
|
1998-12-21 |
2006-04-15 |
Ludwig Inst Cancer Res |
Antikörper gegen verkürzten vegf-d und deren verwendungen
|
IT1312077B1
(it)
*
|
1999-04-15 |
2002-04-04 |
Univ Degli Studi Milano |
Polipeptidi ad attivita' antiangiogenica.
|
US6703020B1
(en)
|
1999-04-28 |
2004-03-09 |
Board Of Regents, The University Of Texas System |
Antibody conjugate methods for selectively inhibiting VEGF
|
ES2223705T3
(es)
*
|
1999-04-28 |
2005-03-01 |
Board Of Regents, The University Of Texas System |
Composiciones y metodos para el tratamiento de cancer mediante inhibi cion selectiva del vegf.
|
US6924359B1
(en)
|
1999-07-01 |
2005-08-02 |
Yale University |
Neovascular-targeted immunoconjugates
|
JP4776843B2
(ja)
|
1999-10-01 |
2011-09-21 |
イムノゲン インコーポレーティッド |
免疫複合体及び化学療法剤を用いる癌治療用組成物及び方法
|
US7303749B1
(en)
|
1999-10-01 |
2007-12-04 |
Immunogen Inc. |
Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
|
JP2003511356A
(ja)
*
|
1999-10-06 |
2003-03-25 |
ビーエーエスエフ アクチェンゲゼルシャフト |
併用療法のためのサイトカイン媒介性シグナル伝達経路のモジュレーター及びインテグリンαvβ3受容体アンタゴニスト
|
US7740841B1
(en)
*
|
2000-01-28 |
2010-06-22 |
Sunnybrook Health Science Center |
Therapeutic method for reducing angiogenesis
|
US7125542B2
(en)
*
|
2000-02-10 |
2006-10-24 |
Massachusetts Eye And Ear Infirmary |
Methods and compositions for treating conditions of the eye
|
AU2001242432B2
(en)
*
|
2000-02-24 |
2007-11-08 |
Eidgenossische Technische Hochschule Zurich |
Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis
|
US7097840B2
(en)
|
2000-03-16 |
2006-08-29 |
Genentech, Inc. |
Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
|
US20040191260A1
(en)
|
2003-03-26 |
2004-09-30 |
Technion Research & Development Foundation Ltd. |
Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
|
CA2404528A1
(en)
|
2000-03-31 |
2001-10-04 |
Institut Pasteur |
Peptides blocking vascular endothelial growth factor (vegf)-mediated angiogenesis, polynucleotides encoding said peptides and methods of use thereof
|
US7355019B2
(en)
*
|
2000-06-06 |
2008-04-08 |
Sibtech, Inc. |
Cysteine-containing peptide tag for site-specific conjugation of proteins
|
US7288390B2
(en)
*
|
2000-08-07 |
2007-10-30 |
Centocor, Inc. |
Anti-dual integrin antibodies, compositions, methods and uses
|
US7163681B2
(en)
*
|
2000-08-07 |
2007-01-16 |
Centocor, Inc. |
Anti-integrin antibodies, compositions, methods and uses
|
FR2813606B1
(fr)
*
|
2000-09-01 |
2004-04-30 |
Inst Nat Sante Rech Med |
Proteine bard1 tronquee, et ses applications diagnostiques et therapeutiques
|
US8314060B2
(en)
*
|
2000-09-05 |
2012-11-20 |
Biosight Ltd. |
Peptide conjugated anti-cancer prodrugs
|
IL154696A
(en)
*
|
2000-09-05 |
2008-11-03 |
Biosight Ltd |
Peptide conjugated anti-cancer prodrugs
|
CN1246333C
(zh)
*
|
2000-09-07 |
2006-03-22 |
舍林股份公司 |
EDb-纤粘连蛋白结构域(II)的受体
|
US20020091082A1
(en)
*
|
2000-09-13 |
2002-07-11 |
Aiello Lloyd P. |
Methods of modulating symptoms of hypertension
|
JP3712393B2
(ja)
*
|
2000-10-20 |
2005-11-02 |
エーザイ株式会社 |
含窒素芳香環誘導体
|
US7273722B2
(en)
|
2000-11-29 |
2007-09-25 |
Allergan, Inc. |
Neurotoxins with enhanced target specificity
|
US20050209310A1
(en)
*
|
2000-12-22 |
2005-09-22 |
Chaplin David J |
Methods for modulating tumor growth and metastasis
|
US7037906B1
(en)
*
|
2000-12-22 |
2006-05-02 |
Oxigene, Inc. |
Methods for modulating tumor growth and metastasis
|
AU2002327164A1
(en)
*
|
2001-01-29 |
2002-12-09 |
Idec Pharmaceuticals Corporation |
Engineered tetravalent antibodies and methods of use
|
CN1494553A
(zh)
*
|
2001-01-29 |
2004-05-05 |
IDECҩ�﹫˾ |
改变的抗体及其使用方法
|
US20030077826A1
(en)
*
|
2001-02-02 |
2003-04-24 |
Lena Edelman |
Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (PTPC)
|
US7601825B2
(en)
|
2001-03-05 |
2009-10-13 |
Agensys, Inc. |
Nucleic acid and corresponding protein entitled 121P1F1 useful in treatment and detection of cancer
|
US6924358B2
(en)
*
|
2001-03-05 |
2005-08-02 |
Agensys, Inc. |
121P1F1: a tissue specific protein highly expressed in various cancers
|
CN100589845C
(zh)
*
|
2001-03-07 |
2010-02-17 |
麦康公司 |
用于治疗癌症的抗新血管系统制剂
|
US20030068319A1
(en)
*
|
2001-03-23 |
2003-04-10 |
Menashe Bar-Eli |
Methods for inhibition of angiogenesis, tumor growth and metastasis by fully human anti-IL8 and anti-MUC18 in diverse types of tumors
|
WO2002079254A1
(en)
*
|
2001-03-29 |
2002-10-10 |
Janoff Edward N |
Human monoclonal antibodies against capsular polysaccharides of streptococcus pneumoniae
|
WO2002081649A2
(en)
|
2001-04-06 |
2002-10-17 |
The Trustees Of The University Of Pennsylvania |
ErbB INTERFACE PEPTIDOMIMETICS AND METHODS OF USE THEREOF
|
US20030191073A1
(en)
*
|
2001-11-07 |
2003-10-09 |
Challita-Eid Pia M. |
Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
|
WO2002083850A2
(en)
*
|
2001-04-13 |
2002-10-24 |
Human Genome Sciences, Inc. |
Vascular endothelial growth factor 2
|
KR20030093316A
(ko)
|
2001-04-13 |
2003-12-06 |
휴먼 게놈 사이언시즈, 인코포레이티드 |
혈관 내피 성장 인자 2
|
US6884869B2
(en)
*
|
2001-04-30 |
2005-04-26 |
Seattle Genetics, Inc. |
Pentapeptide compounds and uses related thereto
|
US7256257B2
(en)
|
2001-04-30 |
2007-08-14 |
Seattle Genetics, Inc. |
Pentapeptide compounds and uses related thereto
|
EP1401875A4
(de)
*
|
2001-05-04 |
2005-01-26 |
Univ Utah Res Found |
Hyaluronsäure enthaltende biokonjugate: gezielte abgabe von antikrebsmitteln an krebszellen
|
US7456146B2
(en)
*
|
2001-05-09 |
2008-11-25 |
Ghc Research Development Corporation |
Lytic peptide prodrugs
|
US20090226429A1
(en)
*
|
2001-05-25 |
2009-09-10 |
Human Genome Sciences, Inc. |
Antibodies That Immunospecifically Bind to TRAIL Receptors
|
US7361341B2
(en)
*
|
2001-05-25 |
2008-04-22 |
Human Genome Sciences, Inc. |
Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
|
EP1390069A1
(de)
*
|
2001-05-30 |
2004-02-25 |
Cornell Research Foundation, Inc. |
Endopeptidase/anti-psma-antikörper-fusionsproteine zur behandlung von krebs
|
US7666414B2
(en)
*
|
2001-06-01 |
2010-02-23 |
Cornell Research Foundation, Inc. |
Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen
|
JP4619651B2
(ja)
*
|
2001-06-01 |
2011-01-26 |
コーネル・リサーチ・ファンデーション・インコーポレイテッド |
前立腺特異的膜抗原に対する修飾抗体およびその使用
|
US7514078B2
(en)
*
|
2001-06-01 |
2009-04-07 |
Cornell Research Foundation, Inc. |
Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
|
JP2005501011A
(ja)
*
|
2001-06-08 |
2005-01-13 |
ユタ ベンチャー ザ セカンド リミテッド パートナーシップ |
組織特異的内皮膜タンパク質
|
EP1515707A4
(de)
*
|
2001-06-20 |
2005-10-19 |
Imclone Systems Inc |
Verfahren zur behandlung von atherosklerose und anderer entzündlicher erkrankungen
|
EP1423428B2
(de)
*
|
2001-06-20 |
2012-11-14 |
Fibron Ltd. |
Fgfr3 blockierende antikörper, verfahren zum screening darauf und verwendungen davon
|
US20050271663A1
(en)
*
|
2001-06-28 |
2005-12-08 |
Domantis Limited |
Compositions and methods for treating inflammatory disorders
|
ATE477280T1
(de)
*
|
2001-06-28 |
2010-08-15 |
Domantis Ltd |
Doppelspezifischer ligand und dessen verwendung
|
WO2004003019A2
(en)
*
|
2002-06-28 |
2004-01-08 |
Domantis Limited |
Immunoglobin single variant antigen-binding domains and dual-specific constructs
|
US20060073141A1
(en)
*
|
2001-06-28 |
2006-04-06 |
Domantis Limited |
Compositions and methods for treating inflammatory disorders
|
WO2003006059A1
(en)
*
|
2001-07-13 |
2003-01-23 |
Imclone Systems Incorporated |
Vegfr-1 antibodies to treat breast cancer
|
US7662374B2
(en)
*
|
2001-08-03 |
2010-02-16 |
The Trustees Of The University Of Pennsylvania |
Monoclonal antibodies to activated erbB family members and methods of use thereof
|
WO2003014326A2
(en)
*
|
2001-08-10 |
2003-02-20 |
Imclone Systems Incorporated |
Isolation and mobilization of stem cells expressing vegfr-1
|
US7494646B2
(en)
|
2001-09-06 |
2009-02-24 |
Agensys, Inc. |
Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
|
EP2287186B1
(de)
*
|
2001-09-06 |
2014-12-31 |
Agensys, Inc. |
Nucleinsäure und entsprechendes Protein, STEAP-1, bei der Behandlung und zum Nachweis von Krebs
|
WO2003024388A2
(en)
*
|
2001-09-20 |
2003-03-27 |
Cornell Research Foundation, Inc. |
Methods and compositions for treating and preventing skin disorders using binding agents specific for psma
|
US20030129193A1
(en)
*
|
2001-09-27 |
2003-07-10 |
Board Of Regents, The University Of Texas System And Peregrine Pharmaceuticals, Inc. |
Combined methods for tumor vasculature coaguligand treatment
|
BR0213303A
(pt)
*
|
2001-10-15 |
2005-06-07 |
Immunomedics Inc |
Proteìnas de ligação de alvejamento direto
|
WO2003040340A2
(en)
*
|
2001-11-07 |
2003-05-15 |
Agensys, Inc. |
Nucleic acid and corresponding protein entitled 161p2f10b useful in treatment and detection of cancer
|
GB0126879D0
(en)
*
|
2001-11-08 |
2002-01-02 |
Astrazeneca Ab |
Combination therapy
|
WO2003047633A2
(en)
*
|
2001-12-04 |
2003-06-12 |
Nanospectra Biosciences, Inc. |
Treatment of angiogenesis disorders using targeted nanoparticles
|
JP2005516965A
(ja)
*
|
2001-12-28 |
2005-06-09 |
アブジェニックス・インコーポレーテッド |
抗muc18抗体を使用する方法
|
US20030194421A1
(en)
*
|
2001-12-28 |
2003-10-16 |
Angiotech Pharmaceuticals, Inc. |
Treatment of uveitis
|
DE60226499D1
(de)
|
2001-12-28 |
2008-06-19 |
Amgen Fremont Inc |
Verwendung von antikörpern gegen das muc18-antigen
|
AU2002367318B2
(en)
*
|
2002-01-02 |
2007-07-12 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
EP2239274A1
(de)
*
|
2002-01-03 |
2010-10-13 |
Bayer Schering Pharma AG |
Neue Verfahren zur Diagnose und Behandlung von Tumoren
|
JP4242590B2
(ja)
|
2002-01-11 |
2009-03-25 |
俊一 塩澤 |
慢性関節リウマチの疾患感受性遺伝子、及びその利用
|
US20050069549A1
(en)
|
2002-01-14 |
2005-03-31 |
William Herman |
Targeted ligands
|
US20080063639A1
(en)
*
|
2002-01-18 |
2008-03-13 |
Pierre Fabre Medicament |
Method for the treatment of psoriasis comprising novel anti-IGF-IR antibodies
|
US7241444B2
(en)
*
|
2002-01-18 |
2007-07-10 |
Pierre Fabre Medicament |
Anti-IGF-IR antibodies and uses thereof
|
US20080193445A1
(en)
*
|
2002-01-18 |
2008-08-14 |
Liliane Goetsch |
Novel anti-IGF-IR antibodies and uses thereof
|
IL152904A0
(en)
*
|
2002-01-24 |
2003-06-24 |
Gamida Cell Ltd |
Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
|
CA2472578A1
(en)
*
|
2002-01-24 |
2003-07-31 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Anti-cancer combination and use thereof
|
WO2003062404A1
(en)
*
|
2002-01-25 |
2003-07-31 |
Gamida-Cell Ltd. |
Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby
|
US20050042632A1
(en)
*
|
2002-02-13 |
2005-02-24 |
Sirna Therapeutics, Inc. |
Antibodies having specificity for nucleic acids
|
US7071311B2
(en)
*
|
2002-02-13 |
2006-07-04 |
Sirna Therapeutics, Inc. |
Antibodies having specificity for 2′-C-allyl nucleic acids
|
US6992176B2
(en)
*
|
2002-02-13 |
2006-01-31 |
Technion Research & Development Foundation Ltd. |
Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
|
US20030223994A1
(en)
*
|
2002-02-20 |
2003-12-04 |
Hoogenboom Henricus Renerus Jacobus Mattheus |
MHC-peptide complex binding ligands
|
US8435529B2
(en)
|
2002-06-14 |
2013-05-07 |
Immunomedics, Inc. |
Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
|
US8491896B2
(en)
*
|
2002-06-14 |
2013-07-23 |
Immunomedics, Inc. |
Anti-pancreatic cancer antibodies
|
ES2362931T3
(es)
*
|
2002-03-04 |
2011-07-15 |
Imclone Llc |
Anticuerpos humanos específicos contra kdr y usos de los mismos.
|
SG108837A1
(en)
*
|
2002-03-11 |
2005-02-28 |
Pi Eta Consulting Co Pte Ltd |
An enterprise knowledge and information acquisition, management and communications system with intelligent user interfaces
|
AU2003218194A1
(en)
*
|
2002-03-15 |
2003-09-29 |
Attenuon, Llc |
Cell surface tropomyosin as a target of angiogenesis inhibition
|
US20060002940A1
(en)
*
|
2002-03-15 |
2006-01-05 |
Jennifer Stevenson |
Method of immunotherapy
|
US20070178065A1
(en)
*
|
2002-05-03 |
2007-08-02 |
Lattime Edmund C |
Neutralizing factors as vaccine adjuvants
|
US20050169883A1
(en)
*
|
2002-05-06 |
2005-08-04 |
Prestwich Glenn D. |
Preblocking with non-ha gags increases effectiveness of ha conjugated anticancer agents
|
DE60326950D1
(de)
*
|
2002-05-15 |
2009-05-14 |
Janssen Pharmaceutica Nv |
N-substituierte tricyclische 3-aminopyrazole als pdgf rezeptorenhemmer
|
JP4405916B2
(ja)
|
2002-05-23 |
2010-01-27 |
トラスティース・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア |
Fasペプチド模倣体およびその使用
|
AU2003241024A1
(en)
*
|
2002-05-29 |
2003-12-19 |
Immunomedics, Inc. |
Methods and compositions for radioimmunotherapy of brain and cns tumors
|
JP4511108B2
(ja)
*
|
2002-05-31 |
2010-07-28 |
オンコリクス インコーポレイテッド |
ヒトプロラクチン拮抗剤−血管新生阻害剤融合蛋白質
|
US20040022726A1
(en)
*
|
2002-06-03 |
2004-02-05 |
Goldenberg David M. |
Methods and compositions for intravesical therapy of bladder cancer
|
CN1675245B
(zh)
*
|
2002-06-14 |
2011-01-12 |
免疫医疗公司 |
人源化单克隆抗体hPAM4
|
US9599619B2
(en)
|
2002-06-14 |
2017-03-21 |
Immunomedics, Inc. |
Anti-pancreatic cancer antibodies
|
WO2003106497A1
(en)
*
|
2002-06-14 |
2003-12-24 |
Immunomedics, Inc. |
Monoclonal antibody pam4 and its use for diagnosis and therapy of pancreatic cancer
|
US8821868B2
(en)
|
2002-06-14 |
2014-09-02 |
Immunomedics, Inc. |
Anti-pancreatic cancer antibodies
|
US7696320B2
(en)
|
2004-08-24 |
2010-04-13 |
Domantis Limited |
Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
|
US9321832B2
(en)
*
|
2002-06-28 |
2016-04-26 |
Domantis Limited |
Ligand
|
EP1537146B9
(de)
|
2002-07-15 |
2011-07-06 |
Board Of Regents, The University Of Texas System |
Antikörper mit bindung an anionische phospholipide und aminophospholipide und ihre verwendung bei der behandlung von virusinfektionen
|
EP1546121B1
(de)
|
2002-07-18 |
2012-08-29 |
Janssen Pharmaceutica NV |
Substituierte triazin-kinaseinhibitoren
|
NZ520321A
(en)
*
|
2002-07-19 |
2005-03-24 |
Auckland Uniservices Ltd |
Use of an agent adapted to inhibit HIF in use together with an antiangiogenic agent for treating tumours in a non- human animal
|
SI2357006T1
(sl)
*
|
2002-07-31 |
2016-01-29 |
Seattle Genetics, Inc. |
Konjugati zdravil in njihova uporaba za zdravljenje raka, avtoimunske bolezni ali infekcijske bolezni
|
PL219749B1
(pl)
*
|
2002-08-16 |
2015-07-31 |
Janssen Pharmaceutica Nv |
Pochodna piperydyny i jej zastosowanie oraz kompozycja farmaceutyczna ją zawierająca
|
US20040224986A1
(en)
|
2002-08-16 |
2004-11-11 |
Bart De Corte |
Piperidinyl targeting compounds that selectively bind integrins
|
US7226755B1
(en)
*
|
2002-09-25 |
2007-06-05 |
The Procter & Gamble Company |
HPTPbeta as a target in treatment of angiogenesis mediated disorders
|
US7507568B2
(en)
*
|
2002-09-25 |
2009-03-24 |
The Proctor & Gamble Company |
Three dimensional coordinates of HPTPbeta
|
ES2533963T3
(es)
*
|
2002-10-10 |
2015-04-16 |
Merck Patent Gmbh |
Composiciones farmacéuticas dirigidas a receptores Erb-B1
|
US9701754B1
(en)
|
2002-10-23 |
2017-07-11 |
City Of Hope |
Covalent disulfide-linked diabodies and uses thereof
|
PT1572748E
(pt)
*
|
2002-12-17 |
2010-09-28 |
Merck Patent Gmbh |
Anticorpo humanizado (h14.18) do anticorpo 14.18 de rato que se liga ao gd2 e a sua fusão com a il-2
|
EP1578801A2
(de)
*
|
2002-12-27 |
2005-09-28 |
Domantis Limited |
Dual-spezifischer einzeldomäne-antikörper welcher spezifisch ist für einen liganden und dessen rezeptor
|
US20050026826A1
(en)
*
|
2003-01-17 |
2005-02-03 |
Margarethe Hoenig |
Feline proinsulin, insulin and constituent peptides
|
US20060039858A1
(en)
*
|
2003-02-11 |
2006-02-23 |
Ekaterina Dadachova |
Radiolabeled antibodies and peptides for treatment of tumors
|
US7402385B2
(en)
*
|
2003-02-11 |
2008-07-22 |
Albert Einstein College Of Medicine Of Yeshiva University |
Radiolabeled antibodies for treatment of tumors
|
US20080025989A1
(en)
*
|
2003-02-20 |
2008-01-31 |
Seattle Genetics, Inc. |
Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
|
AU2004213053C1
(en)
|
2003-02-20 |
2009-07-16 |
Seagen Inc. |
Anti-CD70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
|
US20060104968A1
(en)
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
US7759468B1
(en)
*
|
2003-03-05 |
2010-07-20 |
University Of Kentucky Research Foundation |
Bioactive peptide-based probes
|
US20060231107A1
(en)
*
|
2003-03-07 |
2006-10-19 |
Glickman Randolph D |
Antibody-targeted photodynamic therapy
|
JPWO2004080462A1
(ja)
*
|
2003-03-10 |
2006-06-08 |
エーザイ株式会社 |
c−Kitキナーゼ阻害剤
|
PT1608685E
(pt)
*
|
2003-03-28 |
2007-05-31 |
Regeneron Pharma |
Anatagonistas de vegf para o tratamento de diabetes.
|
US8088387B2
(en)
|
2003-10-10 |
2012-01-03 |
Immunogen Inc. |
Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
|
JP4703567B2
(ja)
*
|
2003-05-23 |
2011-06-15 |
ジェネンテック, インコーポレイテッド |
膠細胞起源の腫瘍の診断と治療のための組成物と方法
|
US9708410B2
(en)
|
2003-05-30 |
2017-07-18 |
Janssen Biotech, Inc. |
Anti-tissue factor antibodies and compositions
|
BRPI0411200A
(pt)
*
|
2003-05-30 |
2006-07-18 |
Genentech Inc |
método de tratamento de cáncer, métodos de tratamento de paciente humano, artigo industrializado e kit de tratamento de cáncer
|
US7605235B2
(en)
*
|
2003-05-30 |
2009-10-20 |
Centocor, Inc. |
Anti-tissue factor antibodies and compositions
|
US20050008649A1
(en)
*
|
2003-06-02 |
2005-01-13 |
University Of Miami |
Chimeric molecules and methods of use
|
WO2005000223A2
(en)
*
|
2003-06-04 |
2005-01-06 |
Children's Medical Center Corporation |
Method of treating retinopathies and disorders associated with blood vessel loss
|
US7178491B2
(en)
*
|
2003-06-05 |
2007-02-20 |
Caterpillar Inc |
Control system and method for engine valve actuator
|
US9005613B2
(en)
|
2003-06-16 |
2015-04-14 |
Immunomedics, Inc. |
Anti-mucin antibodies for early detection and treatment of pancreatic cancer
|
EP2338506A3
(de)
*
|
2003-06-17 |
2011-10-12 |
Mannkind Corporation |
Kombinationen von tumor-assozierten antigenen zur behandlung von verschiedenen krebstypen
|
US7591953B2
(en)
|
2003-06-25 |
2009-09-22 |
Peregrine Pharmaceuticals, Inc. |
Methods and apparatus for continuous large-scale radiolabeling of proteins
|
CN1816351A
(zh)
*
|
2003-06-27 |
2006-08-09 |
艾伯吉尼斯公司 |
针对表皮生长因子受体的缺失突变体的抗体及其使用
|
KR101581040B1
(ko)
*
|
2003-06-27 |
2015-12-30 |
암젠 프레몬트 인코포레이티드 |
상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그 용도
|
WO2005000086A2
(en)
*
|
2003-06-30 |
2005-01-06 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
FRAGMENTS OF NKp44 AND NKp46 FOR TARGETING VIRAL-INFECTED AND TUMOR CELLS
|
AU2004253630B2
(en)
|
2003-07-02 |
2010-11-25 |
Innate Pharma S.A.S. |
Methods for the production and cytotoxicity evaluation of KIR2DL NK-receptor antibodies
|
US20090191213A9
(en)
*
|
2003-07-02 |
2009-07-30 |
Novo Nordisk A/S |
Compositions and methods for regulating NK cell activity
|
AR046510A1
(es)
|
2003-07-25 |
2005-12-14 |
Regeneron Pharma |
Composicion de un antagonista de vegf y un agente anti-proliferativo
|
CA2533878A1
(en)
*
|
2003-07-29 |
2005-09-22 |
Immunomedics, Inc. |
Fluorinated carbohydrate conjugates
|
US7902338B2
(en)
|
2003-07-31 |
2011-03-08 |
Immunomedics, Inc. |
Anti-CD19 antibodies
|
AP2012006644A0
(en)
*
|
2003-08-01 |
2012-12-31 |
Genentech Inc |
Anti-VEGF antibodies
|
US20050106667A1
(en)
|
2003-08-01 |
2005-05-19 |
Genentech, Inc |
Binding polypeptides with restricted diversity sequences
|
AU2012201667B2
(en)
*
|
2003-08-01 |
2014-11-27 |
Genentech, Inc. |
Anti-VEGF antibodies
|
US7758859B2
(en)
*
|
2003-08-01 |
2010-07-20 |
Genentech, Inc. |
Anti-VEGF antibodies
|
WO2005044853A2
(en)
*
|
2003-11-01 |
2005-05-19 |
Genentech, Inc. |
Anti-vegf antibodies
|
WO2005016369A1
(en)
*
|
2003-08-06 |
2005-02-24 |
Regeneron Pharmaceuticals, Inc. |
Use of a vegf antagonist in combination with radiation therapy
|
EP1651663B1
(de)
*
|
2003-08-08 |
2017-05-17 |
Immunomedics, Inc. |
Bispezifische antikörper zur induktion der apoptose in tumorzellen und erkrankten zellen
|
US7547518B2
(en)
*
|
2003-08-19 |
2009-06-16 |
Becton, Dickinson And Company |
Method of screening endothelial cells for angiogenic capability
|
PT1660057E
(pt)
*
|
2003-08-27 |
2012-08-02 |
Ophthotech Corp |
Terapia de associação para o tratamento de distúrbios neovasculares oculares
|
WO2005074417A2
(en)
*
|
2003-09-03 |
2005-08-18 |
Salk Institute For Biological Studies |
Multiple antigen detection assays and reagents
|
CA2543888C
(en)
|
2003-11-06 |
2016-01-19 |
Seattle Genetics, Inc. |
Monomethylvaline compounds capable of conjugation to ligands
|
US7683172B2
(en)
*
|
2003-11-11 |
2010-03-23 |
Eisai R&D Management Co., Ltd. |
Urea derivative and process for preparing the same
|
WO2005047319A2
(en)
*
|
2003-11-12 |
2005-05-26 |
The University Of Georgia Research Foundation, Inc. |
Dna sequence and expressed recombinant glycoproteins related to feline thyrotropin
|
EP1682516A2
(de)
*
|
2003-11-13 |
2006-07-26 |
Janssen Pharmaceutica N.V. |
Immobilisierte n-substituierte tricyclische 3-aminopyrazole zur identifikation biomolekularer ziele
|
WO2005048938A2
(en)
*
|
2003-11-13 |
2005-06-02 |
California Pacific Medical Center |
Anti-pecam therapy for metastasis suppression
|
US20080220049A1
(en)
*
|
2003-12-05 |
2008-09-11 |
Adnexus, A Bristol-Myers Squibb R&D Company |
Compositions and methods for intraocular delivery of fibronectin scaffold domain proteins
|
WO2005056764A2
(en)
|
2003-12-05 |
2005-06-23 |
Compound Therapeutics, Inc. |
Inhibitors of type 2 vascular endothelial growth factor receptors
|
US7799327B2
(en)
*
|
2003-12-24 |
2010-09-21 |
Henry John Smith |
Autoantibodies utilized as carrier agents for pharmaceutical compounds used in cancer treatment
|
US20090155266A1
(en)
*
|
2004-01-16 |
2009-06-18 |
Yale University |
Methods and Compositions Relating to Vascular Endothelial Growth Factor and TH2 Mediated Inflammatory Diseases
|
WO2005072340A2
(en)
*
|
2004-01-27 |
2005-08-11 |
Compugen Ltd. |
Novel polynucleotides encoding polypeptides and methods using same
|
US20110020273A1
(en)
*
|
2005-04-06 |
2011-01-27 |
Ibc Pharmaceuticals, Inc. |
Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof
|
AU2005219413A1
(en)
*
|
2004-03-02 |
2005-09-15 |
Massachusetts Institute Of Technology |
Nanocell drug delivery system
|
US20050214280A1
(en)
*
|
2004-03-02 |
2005-09-29 |
Ludwig Institute For Cancer Research |
Method for inhibiting tumor formation and growth
|
WO2005094882A1
(en)
*
|
2004-03-03 |
2005-10-13 |
Millennium Pharmaceuticals, Inc. |
Modified antibodies to prostate-specific membrane antigen and uses thereof
|
ATE507240T1
(de)
*
|
2004-03-05 |
2011-05-15 |
Vegenics Pty Ltd |
Materialien und verfahren für wachstumsfaktorbindende konstrukte
|
EP1723422A2
(de)
*
|
2004-03-05 |
2006-11-22 |
The Scripps Research Institute |
Glycan-mikroarray mit hohem durchsatz
|
US7745230B2
(en)
*
|
2004-03-10 |
2010-06-29 |
Creighton University |
Estrogen receptors and methods of use
|
AU2012265582B2
(en)
*
|
2004-03-26 |
2015-04-16 |
Ophthotech Corporation |
Combination therapy for the treatment of ocular neovascular disorders
|
JP2008505853A
(ja)
|
2004-04-13 |
2008-02-28 |
クインテセンス バイオサイエンシーズ インコーポレーティッド |
細胞傷害性薬剤としての非天然のリボヌクレアーゼ複合体
|
PT1742966E
(pt)
|
2004-04-22 |
2014-02-05 |
Agensys Inc |
Anticorpos e moléculas derivadas daí que se ligam às proteínas steap-1
|
US20060182783A1
(en)
*
|
2004-04-30 |
2006-08-17 |
Allergan, Inc. |
Sustained release intraocular drug delivery systems
|
CN1304427C
(zh)
*
|
2004-06-08 |
2007-03-14 |
成都康弘生物科技有限公司 |
抑制血管新生的融合蛋白质及其用途
|
US20060159689A1
(en)
*
|
2004-06-17 |
2006-07-20 |
Chih-Sheng Chiang |
Combinations of tumor-associated antigens in diagnostics for various types of cancers
|
US20060008468A1
(en)
*
|
2004-06-17 |
2006-01-12 |
Chih-Sheng Chiang |
Combinations of tumor-associated antigens in diagnostics for various types of cancers
|
WO2006009786A2
(en)
*
|
2004-06-18 |
2006-01-26 |
Elmaleh David R |
Intravascular imaging device and uses thereof
|
US20060008415A1
(en)
*
|
2004-06-25 |
2006-01-12 |
Protein Design Labs, Inc. |
Stable liquid and lyophilized formulation of proteins
|
CA2601417C
(en)
*
|
2004-07-01 |
2018-10-30 |
Novo Nordisk A/S |
Human anti-kir antibodies
|
JP4991532B2
(ja)
*
|
2004-07-02 |
2012-08-01 |
ウォルター アンド エリザ ホール インスティテュート オブ メディカル リサーチ |
アルファヘリックス模倣体
|
CN1997386B
(zh)
*
|
2004-07-30 |
2012-05-30 |
瑞泽恩制药公司 |
通过阻断vegf介导的活性来治疗i型糖尿病的方法
|
DK2299275T3
(en)
|
2004-07-30 |
2018-05-07 |
Adeza Biomedical Corp |
Classification of oncofetal fetronectin level for pregnancy-related indications
|
EP2412728B1
(de)
|
2004-08-03 |
2015-01-07 |
Innate Pharma |
Therapeutische Zusammensetzungen Targeting von 4IG-B7-H3 exprimierenden Tumoren
|
US20070003943A1
(en)
*
|
2004-08-09 |
2007-01-04 |
Northwestern University |
Tumor angiogenesis inhibitor alpha 1-antitrypsin
|
CN1316249C
(zh)
*
|
2004-08-25 |
2007-05-16 |
北京健平九星生物医药科技有限公司 |
一种酶联检测试剂盒及制备方法
|
WO2006024092A1
(en)
*
|
2004-08-31 |
2006-03-09 |
Newsouth Innovations Pty Limited |
Vegf inhibition
|
SV2007002227A
(es)
*
|
2004-09-10 |
2007-03-20 |
Wyeth Corp |
Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/calicheamicina ref. 040000-0317637
|
US8772269B2
(en)
*
|
2004-09-13 |
2014-07-08 |
Eisai R&D Management Co., Ltd. |
Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
|
EP2364699A1
(de)
|
2004-09-13 |
2011-09-14 |
Eisai R&D Management Co., Ltd. |
Gemeinsame Verwendung einer sulfonamidbasierten Verbindung mit Angiogenesehemmer
|
EP1799812A4
(de)
*
|
2004-09-16 |
2009-09-09 |
Gamida Cell Ltd |
Verfahren zur ex-vivo-expansion von progenitor- und stammzellen durch gemeinsame kultivierung mit mesenchymzellen
|
WO2006030826A1
(ja)
*
|
2004-09-17 |
2006-03-23 |
Eisai R & D Management Co., Ltd. |
医薬組成物
|
US8697139B2
(en)
|
2004-09-21 |
2014-04-15 |
Frank M. Phillips |
Method of intervertebral disc treatment using articular chondrocyte cells
|
BRPI0517551A
(pt)
*
|
2004-10-04 |
2008-10-14 |
Cellgate Inc |
análogos de poliamina como agentes terapêuticos para doenças oculares
|
AU2005308539A1
(en)
*
|
2004-10-06 |
2006-06-01 |
Tiltan Pharma Ltd |
Method and composition for enhancing anti-angiogenic therapy
|
US8337838B2
(en)
*
|
2004-10-15 |
2012-12-25 |
Seattle Genetics, Inc. |
Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
|
JP5222559B2
(ja)
*
|
2004-10-15 |
2013-06-26 |
シアトル ジェネティックス, インコーポレイテッド |
癌および免疫障害の処置および予防のための抗cd70抗体ならびにその使用
|
US7641903B2
(en)
*
|
2004-10-15 |
2010-01-05 |
Seattle Genetics, Inc. |
Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
|
PT1802334E
(pt)
*
|
2004-10-21 |
2012-11-28 |
Genentech Inc |
Método para tratamento de doenças neovasculares intraoculares
|
ES2325344B1
(es)
*
|
2004-11-02 |
2010-06-09 |
Univ Madrid Autonoma |
Inhibidores de angiogenesis multifuncionales y multivalentes.
|
US7595149B1
(en)
|
2004-11-08 |
2009-09-29 |
University Of Kentucky Research Foundation |
Methods for cancer detection
|
SI1819358T1
(sl)
|
2004-11-18 |
2014-10-30 |
Imclone Llc |
Protitelesa proti receptorju 1 za vaskularni endotelijski rastni dejavnik (vegfr-1)
|
WO2006068758A2
(en)
*
|
2004-11-19 |
2006-06-29 |
The Scripps Research Institute |
Detection, prevention and treatment of breast cancer
|
MX2007007165A
(es)
*
|
2004-12-17 |
2007-08-14 |
Genentech Inc |
Terapia de antiangiogenesis de enfermedad autoinmune en pacientes en quienes ha fallado la terapia anterior.
|
WO2006068953A2
(en)
|
2004-12-21 |
2006-06-29 |
Astrazeneca Ab |
Antibodies directed to angiopoietin-2 and uses thereof
|
US20120269886A1
(en)
|
2004-12-22 |
2012-10-25 |
Nitto Denko Corporation |
Therapeutic agent for pulmonary fibrosis
|
PT2727583T
(pt)
|
2004-12-22 |
2021-12-27 |
Nitto Denko Corp |
Veículo de fármaco e kit de veículo de fármaco para a inibição da fibrose
|
EP1831258B2
(de)
|
2004-12-28 |
2023-06-07 |
Innate Pharma S.A. |
Monoklonale antikörper gegen nkg2a
|
WO2006071983A2
(en)
|
2004-12-29 |
2006-07-06 |
Mannkind Corporation |
Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines
|
CN101146550B
(zh)
*
|
2004-12-29 |
2013-04-17 |
曼康公司 |
免疫原性组合物用于制备引发和增强免疫应答的试剂盒的用途
|
EP1835937B1
(de)
|
2005-01-06 |
2012-04-11 |
Novo Nordisk A/S |
Zusammensetzungen und verfahren zur behandlung von virusinfektionen
|
WO2006072625A2
(en)
|
2005-01-06 |
2006-07-13 |
Novo Nordisk A/S |
Anti-kir combination treatments and methods
|
US8222376B2
(en)
|
2005-01-06 |
2012-07-17 |
Novo Nordisk A/S |
KIR-binding agents and methods of use thereof
|
US20080248030A1
(en)
*
|
2005-02-02 |
2008-10-09 |
Children's Medical Center Corporation |
Method of Treating Angiogenic Diseases
|
NZ599464A
(en)
|
2005-02-03 |
2014-03-28 |
Topotarget Uk Ltd |
Combination therapies using hdac inhibitors
|
DK1871805T3
(da)
|
2005-02-07 |
2019-12-02 |
Roche Glycart Ag |
Antigenbindende molekyler der binder egfr, vektorer der koder derfor, og anvendelser deraf
|
US20060188508A1
(en)
*
|
2005-02-17 |
2006-08-24 |
Cohen Stanley N |
Methods and compositions for modulating angiogenesis
|
WO2006094026A1
(en)
*
|
2005-03-02 |
2006-09-08 |
Nascent Pharmaceuticals, Inc. |
Pharmaceutically acceptable carrier for ophthalmic compositions
|
AU2006223314A1
(en)
*
|
2005-03-11 |
2006-09-21 |
Regeneron Pharmaceuticals, Inc. |
Treating anemia by inhibition of VEGF
|
CA2598711C
(en)
|
2005-03-25 |
2018-05-29 |
Regeneron Pharmaceuticals, Inc. |
Vegf antagonist formulations
|
AU2006230563B8
(en)
*
|
2005-03-31 |
2010-06-17 |
Agensys, Inc. |
Antibodies and related molecules that bind to 161P2F10B proteins
|
US20060222595A1
(en)
*
|
2005-03-31 |
2006-10-05 |
Priyabrata Mukherjee |
Nanoparticles for therapeutic and diagnostic applications
|
US8350009B2
(en)
*
|
2005-03-31 |
2013-01-08 |
Agensys, Inc. |
Antibodies and related molecules that bind to 161P2F10B proteins
|
EP1712241A1
(de)
*
|
2005-04-15 |
2006-10-18 |
Centre National De La Recherche Scientifique (Cnrs) |
Intratumoral applizierbare Zusammensetzung zur Krebsbehandlung
|
EP1871418B1
(de)
|
2005-04-19 |
2014-03-19 |
Seattle Genetics, Inc. |
Humanisierte, anti-cd70-bindende wirkstoffe und ihre verwendung
|
EP2494969B1
(de)
|
2005-05-13 |
2015-03-25 |
TopoTarget UK Limited |
Pharmazeutische Formulierungen von HDAC-Hemmern
|
US20060269579A1
(en)
*
|
2005-05-25 |
2006-11-30 |
Musculoskeletal Research Llc |
Compositions for treating osteoarthritis
|
US7767710B2
(en)
|
2005-05-25 |
2010-08-03 |
Calosyn Pharma, Inc. |
Method for treating osteoarthritis
|
WO2006130673A1
(en)
*
|
2005-05-31 |
2006-12-07 |
Janssen Pharmaceutica, N.V. |
3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders
|
US7825244B2
(en)
*
|
2005-06-10 |
2010-11-02 |
Janssen Pharmaceutica Nv |
Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis
|
US20060281788A1
(en)
*
|
2005-06-10 |
2006-12-14 |
Baumann Christian A |
Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
|
US20060281768A1
(en)
*
|
2005-06-10 |
2006-12-14 |
Gaul Michael D |
Thienopyrimidine and thienopyridine kinase modulators
|
US8071768B2
(en)
*
|
2005-06-10 |
2011-12-06 |
Janssen Pharmaceutica, N.V. |
Alkylquinoline and alkylquinazoline kinase modulators
|
CN101198620A
(zh)
|
2005-06-17 |
2008-06-11 |
曼康公司 |
激发针对在癌细胞和肿瘤基质上表达的结构域和亚结构域表位的多价免疫应答的方法和组合物
|
EP1748050A1
(de)
*
|
2005-07-28 |
2007-01-31 |
Rijksuniversiteit Groningen |
Aktivierung von Galectinen durch verbesserte Bindung an Zielzellen
|
EP1925941B1
(de)
*
|
2005-08-01 |
2012-11-28 |
Eisai R&D Management Co., Ltd. |
Verfahren zur vorhersage der wirksamkeit eines vaskularisierungsinhibitors
|
WO2007015578A1
(ja)
|
2005-08-02 |
2007-02-08 |
Eisai R & D Management Co., Ltd. |
血管新生阻害物質の効果を検定する方法
|
DE602006020881D1
(de)
|
2005-08-15 |
2011-05-05 |
Vegenics Pty Ltd |
Enen eigenschaften
|
AU2006285673B2
(en)
*
|
2005-09-01 |
2010-12-02 |
Eisai R&D Management Co., Ltd. |
Method for preparation of pharmaceutical composition having improved disintegratability
|
DK1937815T3
(en)
*
|
2005-09-13 |
2015-08-03 |
Nat Res Council Canada |
Methods and compositions for the modulation of tumor cell activity
|
GB0519398D0
(en)
*
|
2005-09-23 |
2005-11-02 |
Antisoma Plc |
Biological materials and uses thereof
|
US20070071756A1
(en)
*
|
2005-09-26 |
2007-03-29 |
Peyman Gholam A |
Delivery of an agent to ameliorate inflammation
|
EA016186B1
(ru)
*
|
2005-09-26 |
2012-03-30 |
Медарекс, Инк. |
Человеческие моноклональные антитела к cd70 и их применение
|
CA2623109C
(en)
|
2005-10-14 |
2019-02-19 |
Innate Pharma |
Nk cell-depleting antibodies for treating immunoproliferative disorders
|
US7795279B2
(en)
|
2005-10-18 |
2010-09-14 |
Janssen Pharmaceutica Nv |
Method of inhibiting FLT3 kinase
|
CN101534865A
(zh)
*
|
2005-10-19 |
2009-09-16 |
Ibc药品公司 |
生物活性装配体的制备方法及其用途
|
WO2007050415A2
(en)
*
|
2005-10-21 |
2007-05-03 |
Medivas, Llc |
Poly(ester urea) polymers and methods of use
|
US20090291437A1
(en)
*
|
2005-11-02 |
2009-11-26 |
O'brien Sean |
Methods for targeting quadruplex sequences
|
EP1949902B1
(de)
|
2005-11-07 |
2012-06-27 |
Eisai R&D Management Co., Ltd. |
Verwendung einer kombination einer anti-angiogenen substanz und c-kit-kinase-hemmer
|
US8041428B2
(en)
|
2006-02-10 |
2011-10-18 |
Electrocore Llc |
Electrical stimulation treatment of hypotension
|
US8812112B2
(en)
*
|
2005-11-10 |
2014-08-19 |
ElectroCore, LLC |
Electrical treatment of bronchial constriction
|
US9037247B2
(en)
|
2005-11-10 |
2015-05-19 |
ElectroCore, LLC |
Non-invasive treatment of bronchial constriction
|
CN101674862A
(zh)
*
|
2005-11-10 |
2010-03-17 |
电子核心公司 |
支气管收缩的电刺激治疗
|
US20110125203A1
(en)
*
|
2009-03-20 |
2011-05-26 |
ElectroCore, LLC. |
Magnetic Stimulation Devices and Methods of Therapy
|
CA2627923C
(en)
*
|
2005-11-10 |
2016-01-12 |
Topotarget Uk Limited |
Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer
|
US20090247576A1
(en)
*
|
2005-11-22 |
2009-10-01 |
Eisai R & D Management Co., Ltd. |
Anti-tumor agent for multiple myeloma
|
US8846393B2
(en)
|
2005-11-29 |
2014-09-30 |
Gamida-Cell Ltd. |
Methods of improving stem cell homing and engraftment
|
AU2006321364B2
(en)
*
|
2005-12-01 |
2011-11-10 |
Domantis Limited |
Noncompetitive domain antibody formats that bind Interleukin 1 Receptor type 1
|
CA2630839C
(en)
†
|
2005-12-16 |
2017-01-17 |
Regeneron Pharmaceuticals, Inc. |
Therapeutic methods for inhibiting tumor growth with dll4 antagonists
|
RS55630B1
(sr)
*
|
2005-12-21 |
2017-06-30 |
Janssen Pharmaceutica Nv |
Triazolopiridazini kao modulatori tirozin kinaze
|
US9572886B2
(en)
|
2005-12-22 |
2017-02-21 |
Nitto Denko Corporation |
Agent for treating myelofibrosis
|
EP1978985A2
(de)
*
|
2005-12-23 |
2008-10-15 |
Board Of Regents Of The University Of Texas System |
Antihyperproliferative therapien gegen hdgf
|
US20090317475A1
(en)
*
|
2006-01-03 |
2009-12-24 |
Beardsley Robert A |
Combination antitumor therapies
|
WO2007129223A2
(en)
*
|
2006-01-23 |
2007-11-15 |
Ad Group |
Systems and methods for distributing emergency messages
|
US20070175313A1
(en)
*
|
2006-01-31 |
2007-08-02 |
Kevin Vandervliet |
MP3 player holder assembly
|
EP1984065B1
(de)
*
|
2006-02-10 |
2012-08-22 |
Electrocore, Inc. |
Behandlung von hypotension durch elektrische stimulation
|
AU2006337679A1
(en)
*
|
2006-02-10 |
2007-08-16 |
Electrocore, Inc. |
Methods and apparatus for treating anaphylaxis using electrical modulation
|
US20070202593A1
(en)
*
|
2006-02-27 |
2007-08-30 |
Research Development Foundation |
Cell-Targeted IKB and Methods for the Use Thereof
|
ES2363891T3
(es)
*
|
2006-03-20 |
2011-08-18 |
The Regents Of The University Of California |
Anticuerpos contra el antígeno de células troncales de la próstata (psca) modificados genéticamente para el direccionamiento al cáncer.
|
TW200812615A
(en)
*
|
2006-03-22 |
2008-03-16 |
Hoffmann La Roche |
Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
|
TWI390034B
(zh)
|
2006-04-06 |
2013-03-21 |
Kyowa Hakko Kirin Co Ltd |
Novel anti-CD98 antibody
|
SMP200800060B
(it)
*
|
2006-04-07 |
2009-07-14 |
Procter & Gamble |
Anticorpi che legano la proteina umana tirosina fosfatasi beta (hptbeta) e loro usi
|
US20100241188A1
(en)
*
|
2009-03-20 |
2010-09-23 |
Electrocore, Inc. |
Percutaneous Electrical Treatment Of Tissue
|
SI2021335T1
(sl)
*
|
2006-04-20 |
2011-09-30 |
Janssen Pharmaceutica Nv |
Heterocikliäśne spojine kot zaviralci c-fms kinaze
|
ES2564781T3
(es)
|
2006-04-20 |
2016-03-29 |
Janssen Pharmaceutica, N.V. |
Inhibidores de la c-fms quinasa
|
WO2007124369A2
(en)
|
2006-04-20 |
2007-11-01 |
Janssen Pharmaceutica N.V. |
Method of inhibiting c kit kinase
|
US8697716B2
(en)
|
2006-04-20 |
2014-04-15 |
Janssen Pharmaceutica Nv |
Method of inhibiting C-KIT kinase
|
US20070253960A1
(en)
*
|
2006-04-28 |
2007-11-01 |
Josee Roy |
Pharmaceutical removal of vascular extensions from a degenerating disc
|
WO2007128526A2
(en)
*
|
2006-05-04 |
2007-11-15 |
Fovea Pharmaceuticals Sa |
Combination comprising a vegf inhibitor and a serine protease for treating neovascular diseases
|
US20070258976A1
(en)
*
|
2006-05-04 |
2007-11-08 |
Ward Keith W |
Combination Therapy for Diseases Involving Angiogenesis
|
US20070265170A1
(en)
*
|
2006-05-15 |
2007-11-15 |
Ola Blixt |
Detection, prevention and treatment of ovarian cancer
|
CN101443009A
(zh)
*
|
2006-05-18 |
2009-05-27 |
卫材R&D管理有限公司 |
针对甲状腺癌的抗肿瘤剂
|
AU2007254167B2
(en)
*
|
2006-05-19 |
2012-11-15 |
Technion Research And Development Foundation Ltd. |
Fusion proteins, uses thereof and processes for producing same
|
WO2007137300A2
(en)
|
2006-05-23 |
2007-11-29 |
Bellicum Pharmaceuticals, Inc. |
Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods
|
US8101721B2
(en)
*
|
2006-06-15 |
2012-01-24 |
Fibron Ltd. |
Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
|
EP2040751A2
(de)
*
|
2006-06-15 |
2009-04-01 |
Biogen Idec MA Inc. |
Kombinationstherapie mit lymphotoxin beta rezeptor-bindungsmolekülen in kombination mit sekundären mitteln
|
DK2944306T3
(da)
|
2006-06-16 |
2021-03-08 |
Regeneron Pharma |
Egnede VEGF-antagonistformuleringer til intravitreal administration
|
JP2009541333A
(ja)
*
|
2006-06-23 |
2009-11-26 |
クインテセンス バイオサイエンシーズ インコーポレーティッド |
修飾リボヌクレアーゼ
|
US7795444B2
(en)
*
|
2006-06-27 |
2010-09-14 |
Warner Chilcott Company |
Human protein tyrosine phosphatase inhibitors and methods of use
|
US8846685B2
(en)
|
2006-06-27 |
2014-09-30 |
Aerpio Therapeutics Inc. |
Human protein tyrosine phosphatase inhibitors and methods of use
|
US7622593B2
(en)
|
2006-06-27 |
2009-11-24 |
The Procter & Gamble Company |
Human protein tyrosine phosphatase inhibitors and methods of use
|
US7589212B2
(en)
|
2006-06-27 |
2009-09-15 |
Procter & Gamble Company |
Human protein tyrosine phosphatase inhibitors and methods of use
|
US20090203693A1
(en)
*
|
2006-06-29 |
2009-08-13 |
Eisai R & D Management Co., Ltd. |
Therapeutic agent for liver fibrosis
|
WO2008036449A2
(en)
*
|
2006-06-29 |
2008-03-27 |
The Regents Of The University Of California |
Chemical antibodies for immunotherapy and imaging
|
EP2049151A4
(de)
|
2006-07-17 |
2010-03-24 |
Quintessence Biosciences Inc |
Verfahren und zusammensetzungen zur behandlung von krebs
|
BRPI0714981A2
(pt)
*
|
2006-07-28 |
2013-08-13 |
Sanofi Aventis |
composiÇço, mÉtodo para fazer a mesma a qual compreende um inibidor que inibe a atividade de uma proteÍna do complexo iii, um veÍculo e um membro da superfamÍlia da fator de necrose de tumor, mÉtodo para conduzir um ensaio para determinar se um composto É um inibidor de atividade de supressço de tnf de uma proteÍna do complexo iii e uso de um composto
|
AR062223A1
(es)
*
|
2006-08-09 |
2008-10-22 |
Glycart Biotechnology Ag |
Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas
|
WO2008026748A1
(fr)
*
|
2006-08-28 |
2008-03-06 |
Eisai R & D Management Co., Ltd. |
Agent antitumoral pour cancer gastrique non différencié
|
US20080070855A1
(en)
*
|
2006-09-20 |
2008-03-20 |
James Pitzer Gills |
Treatment with anti-VEGF agents to prevent postoperative inflammation and angiogenesis in normal and diseased eyes
|
BRPI0717431A2
(pt)
*
|
2006-09-29 |
2013-11-12 |
Oncomed Pharm Inc |
Composições e métodos de diagnóstico e tratamento do câncer
|
EA200900562A1
(ru)
*
|
2006-10-17 |
2009-10-30 |
Дайэкс Корп. |
Способ лечения расстройства, связанного с ангиогенезом
|
US8975374B2
(en)
*
|
2006-10-20 |
2015-03-10 |
Chugai Seiyaku Kabushiki Kaisha |
Pharmaceutical composition comprising anti-HB-EGF antibody as active ingredient
|
EP2093237B1
(de)
|
2006-10-20 |
2015-12-30 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-hb-egf-antikörper als anti-krebs wirkstoff
|
AU2007311957A1
(en)
*
|
2006-10-20 |
2008-04-24 |
Forerunner Pharma Research Co., Ltd. |
Pharmaceutical composition comprising anti-HB-EGF antibody as active ingredient
|
PL2087002T3
(pl)
*
|
2006-10-27 |
2015-02-27 |
Lpath Inc |
Kompozycje i sposoby do wiązania sfingozyno-1 fosforanu
|
WO2008052187A2
(en)
*
|
2006-10-27 |
2008-05-02 |
Genentech. Inc. |
Antibodies and immunoconjugates and uses therefor
|
CN101687031B
(zh)
*
|
2006-10-27 |
2014-05-14 |
勒帕斯公司 |
用于治疗眼疾和眼病的组合物及方法
|
US20100029674A1
(en)
|
2006-11-17 |
2010-02-04 |
Innate Pharma, S.A. |
Methods of Using Phosphoantigen for the Treatment of Cancer
|
JP5537946B2
(ja)
|
2006-11-22 |
2014-07-02 |
ブリストル−マイヤーズ スクイブ カンパニー |
Igf−irを含むチロシンキナーゼ受容体に対する改変タンパク質に基づく標的治療薬
|
WO2008064336A2
(en)
|
2006-11-22 |
2008-05-29 |
Inivitrogen Corporation |
Autoimmune disease biomarkers
|
NZ578354A
(en)
*
|
2006-12-14 |
2012-01-12 |
Medarex Inc |
Antibody-partner molecule conjugates that bind cd70 and uses thereof
|
AU2007333735A1
(en)
*
|
2006-12-19 |
2008-06-26 |
Genentech, Inc. |
VEGF-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
|
WO2008074853A1
(en)
*
|
2006-12-21 |
2008-06-26 |
Novartis Ag |
Ophthalmic rebamipide solution
|
JP5618172B2
(ja)
*
|
2007-01-05 |
2014-11-05 |
国立大学法人東京大学 |
抗prg−3抗体を用いる癌の診断および治療
|
WO2008089070A2
(en)
*
|
2007-01-12 |
2008-07-24 |
Dyax Corp. |
Combination therapy for the treatment of cancer
|
EP2119707B1
(de)
*
|
2007-01-29 |
2015-01-14 |
Eisai R&D Management Co., Ltd. |
Zusammensetzung zur behandlung von nicht differenzierten formen von magenkrebsen
|
US7816390B2
(en)
*
|
2007-01-31 |
2010-10-19 |
Janssen Pharmaceutica Nv |
N-substituted tricyclic 3-aminopyrazoles as anti-mitotic tubulin polymerization inhibitors
|
US20100144599A1
(en)
*
|
2007-02-02 |
2010-06-10 |
Bristol-Myers Squibb Company |
Vegf pathway blockade
|
WO2008093246A2
(en)
*
|
2007-02-02 |
2008-08-07 |
Vegenics Limited |
Vegf receptor antagonist for treating organ transplant alloimmunity and arteriosclerosis
|
TWI407971B
(zh)
|
2007-03-30 |
2013-09-11 |
Nitto Denko Corp |
Cancer cells and tumor-related fibroblasts
|
US20080286337A1
(en)
*
|
2007-05-15 |
2008-11-20 |
Boston Foundation For Sight |
Method of treating a disease in an eye using a scleral lens
|
CA2683801A1
(en)
*
|
2007-06-06 |
2008-12-11 |
Domantis Limited |
Polypeptides, antibody variable domains and antagonists
|
KR100883430B1
(ko)
|
2007-06-13 |
2009-02-12 |
한국생명공학연구원 |
혈관내피성장인자 수용체를 중화하는 인간 단클론항체 및그 용도
|
PE20090368A1
(es)
*
|
2007-06-19 |
2009-04-28 |
Boehringer Ingelheim Int |
Anticuerpos anti-igf
|
US8097422B2
(en)
|
2007-06-20 |
2012-01-17 |
Salk Institute For Biological Studies |
Kir channel modulators
|
US20090047689A1
(en)
*
|
2007-06-20 |
2009-02-19 |
John Kolman |
Autoantigen biomarkers for early diagnosis of lung adenocarcinoma
|
JP5548123B2
(ja)
*
|
2007-06-21 |
2014-07-16 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
6−{ジフルオロ[6−(1−メチル−1H−ピラゾル−4−イル)[1,2,4]トリアゾロ[4,3−b]ピリダジン−3−イル]メチル}キノリンの多形および水和物の形態、塩、ならびに製造方法
|
US8334239B2
(en)
|
2007-07-10 |
2012-12-18 |
The Board Of Regents Of The University Of Texas System |
High affinity VEGF-receptor antagonists
|
DK2474557T3
(da)
|
2007-07-16 |
2014-11-10 |
Genentech Inc |
Anti-CD79b-antistoffer og immunkonjugater og fremgangsmåder til anvendelse
|
ES2528922T3
(es)
|
2007-07-16 |
2015-02-13 |
Genentech, Inc. |
Anticuerpos anti-CD79b humanizados e inmunoconjugados y métodos de uso
|
JP2010538972A
(ja)
*
|
2007-08-20 |
2010-12-16 |
ブリストル−マイヤーズ スクイブ カンパニー |
転移性癌の処置のためのvegfr−2阻害剤の使用
|
US20090304719A1
(en)
|
2007-08-22 |
2009-12-10 |
Patrick Daugherty |
Activatable binding polypeptides and methods of identification and use thereof
|
CA2698343C
(en)
|
2007-09-04 |
2018-06-12 |
The Regents Of The University Of California |
High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
|
WO2009036368A2
(en)
*
|
2007-09-14 |
2009-03-19 |
Nitto Denko Corporation |
Drug carriers
|
EP2203421B1
(de)
*
|
2007-09-25 |
2014-05-07 |
TopoTarget UK Limited |
Verfahren zur synthese bestimmter n-hydroxy-3-(3-phenylsulfamoyl-phenyl)-acrylamiden verbindungen
|
US20090163440A1
(en)
*
|
2007-09-26 |
2009-06-25 |
Waddell David D |
Ion-Channel Regulator Compositions and Methods of Using Same
|
EP2740490A1
(de)
*
|
2007-10-03 |
2014-06-11 |
Cornell University |
Behandlung von proliferativen Erkrankungen mit PSMA-Antikörpern
|
US8697062B2
(en)
*
|
2007-10-08 |
2014-04-15 |
Quintessence Biosciences, Inc. |
Compositions and methods for ribonuclease-based therapeutics
|
JO3240B1
(ar)
*
|
2007-10-17 |
2018-03-08 |
Janssen Pharmaceutica Nv |
c-fms مثبطات كيناز
|
US8361465B2
(en)
*
|
2007-10-26 |
2013-01-29 |
Lpath, Inc. |
Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents
|
WO2009061830A1
(en)
*
|
2007-11-06 |
2009-05-14 |
Massachusetts Eye & Ear Infirmary |
Methods and compositions for treating conditions associated with angiogenesis using a vascular adhesion protein-1 (vap-1) inhibitor
|
WO2009062174A1
(en)
*
|
2007-11-08 |
2009-05-14 |
University Of Utah Research Foundation |
Use of angiogenesis antagonists in conditions of abnormal venous proliferation
|
AU2013205269B2
(en)
*
|
2007-11-09 |
2016-05-19 |
Affitech Research As |
Anti-VEGF antibody compositions and methods
|
MX2010005104A
(es)
*
|
2007-11-09 |
2010-08-04 |
Peregrine Pharmaceuticals Inc |
Composiciones de anticuerpo anti-factor de crecimiento endotelial vascular y metodos.
|
EP2218712B1
(de)
|
2007-11-09 |
2015-07-01 |
Eisai R&D Management Co., Ltd. |
Kombination einer antiangiogenen substanz und eines platinkomplexes mit antitumorwirkung
|
ES2369717T3
(es)
*
|
2007-11-30 |
2011-12-05 |
F. Hoffmann-La Roche Ag |
Estabilización de conjugados que comprenden una molécula conectora de tiourea.
|
TWI580694B
(zh)
*
|
2007-11-30 |
2017-05-01 |
建南德克公司 |
抗-vegf抗體
|
US8253725B2
(en)
*
|
2007-12-28 |
2012-08-28 |
St. Jude Medical, Atrial Fibrillation Division, Inc. |
Method and system for generating surface models of geometric structures
|
UA100255C2
(uk)
*
|
2007-12-28 |
2012-12-10 |
Біоінвент Інтернешенл Аб |
Фармацевтична композиція
|
US9358307B2
(en)
*
|
2008-01-25 |
2016-06-07 |
Gavish-Galilee Bio Applications Ltd. |
Targeting of innate immune response to tumor site
|
CN102036962B
(zh)
*
|
2008-01-29 |
2013-08-07 |
卫材R&D管理有限公司 |
血管生成抑制剂和紫杉烷的组合使用
|
AU2009210636B2
(en)
|
2008-01-31 |
2014-08-28 |
Genentech, Inc. |
Anti-CD79b antibodies and immunoconjugates and methods of use
|
WO2009102421A2
(en)
|
2008-02-14 |
2009-08-20 |
Bristol-Myers Squibb Company |
Targeted therapeutics based on engineered proteins that bind egfr
|
DK2262493T3
(en)
*
|
2008-03-07 |
2015-04-27 |
Onxeo Dk Branch Of Onxeo S A France |
METHODS OF TREATMENT WITH prolonged continuous infusion of Belinostat
|
DK2254571T3
(en)
|
2008-03-18 |
2015-09-28 |
Genentech Inc |
Combinations of an anti-HER2 antibody-drug conjugate and the chemotherapeutic agents and methods of using
|
WO2009120178A1
(en)
*
|
2008-03-26 |
2009-10-01 |
Epitomics, Inc. |
Anti-vegf antibody
|
AU2014202474B2
(en)
*
|
2008-03-26 |
2016-07-28 |
Epitomics, Inc. |
Anti-VEGF antibody
|
KR100998569B1
(ko)
*
|
2008-03-31 |
2010-12-07 |
한국원자력연구원 |
암 또는 전이암 진단 및 치료용 방사면역접합체,및 이를이용한 암 또는 전이암 억제제 개발
|
WO2009125394A1
(en)
*
|
2008-04-09 |
2009-10-15 |
Technion Research & Development Foundation Ltd. |
Anti human immunodeficiency antibodies and uses thereof
|
CN102083615B
(zh)
*
|
2008-04-10 |
2014-08-13 |
战略系统有限公司 |
用于三维模型打印的系统和方法
|
JP5624535B2
(ja)
|
2008-05-02 |
2014-11-12 |
シアトル ジェネティクス,インコーポレーテッド |
低いコアフコシル化を有する抗体及び抗体誘導体を調製するための方法並びに組成物
|
CA2723277A1
(en)
|
2008-05-02 |
2009-11-05 |
Novartis Ag |
Improved fibronectin-based binding molecules and uses thereof
|
ES2338400B1
(es)
*
|
2008-05-06 |
2011-09-14 |
David Benet Ferrus |
Conjunto de moleculas antiangiogenicas y su uso.
|
US8082730B2
(en)
*
|
2008-05-20 |
2011-12-27 |
Caterpillar Inc. |
Engine system having particulate reduction device and method
|
WO2009142773A2
(en)
|
2008-05-22 |
2009-11-26 |
Bristol-Myers Squibb Company |
Multivalent fibronectin based scaffold domain proteins
|
US20090298088A1
(en)
*
|
2008-05-30 |
2009-12-03 |
Belyaev Alexander S |
Cleavable catalytic binding and detection system
|
HUE032894T2
(hu)
|
2008-06-25 |
2017-11-28 |
Esbatech Alcon Biomed Res Unit |
VEGF-gátló, stabilis és oldható antitestek
|
US20100069616A1
(en)
*
|
2008-08-06 |
2010-03-18 |
The Regents Of The University Of California |
Engineered antibody-nanoparticle conjugates
|
CN102227443B
(zh)
|
2008-10-01 |
2014-05-14 |
昆特森斯生物科学公司 |
治疗性核糖核酸酶
|
US9434610B2
(en)
*
|
2008-10-07 |
2016-09-06 |
Rexahn Pharmaceuticals, Inc. |
HPMA—docetaxel conjugates and uses therefore
|
US8871202B2
(en)
|
2008-10-24 |
2014-10-28 |
Lpath, Inc. |
Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
|
DK3290052T3
(da)
|
2008-11-07 |
2020-02-03 |
Galaxy Biotech Llc |
Monoklonale antistoffer mod fibroblastvækstfaktorreceptor 2
|
PA8849001A1
(es)
|
2008-11-21 |
2010-06-28 |
Lilly Co Eli |
Anticuerpos de c-met
|
TWI496582B
(zh)
|
2008-11-24 |
2015-08-21 |
必治妥美雅史谷比公司 |
雙重專一性之egfr/igfir結合分子
|
KR101093717B1
(ko)
|
2008-11-26 |
2011-12-19 |
한국생명공학연구원 |
Vegf―특이적인 인간항체
|
EA029178B1
(ru)
|
2008-12-12 |
2018-02-28 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Антитела против инсулиноподобных факторов роста, молекула днк, вектор, клетка-хозяин, предназначенные для получения этого антитела, способ его получения и применение
|
RU2636046C2
(ru)
*
|
2009-01-12 |
2017-11-17 |
Сайтомкс Терапьютикс, Инк |
Композиции модифицированных антител, способы их получения и применения
|
GB0900555D0
(en)
*
|
2009-01-14 |
2009-02-11 |
Topotarget As |
New methods
|
WO2010087994A2
(en)
|
2009-01-30 |
2010-08-05 |
Whitehead Institute For Biomedical Research |
Methods for ligation and uses thereof
|
WO2010091234A2
(en)
|
2009-02-06 |
2010-08-12 |
The General Hospital Corporation |
Methods of treating vascular lesions
|
DK3903829T3
(da)
|
2009-02-13 |
2023-06-26 |
Immunomedics Inc |
Immunkonjugater med en intracellulær spaltelig binding
|
ES2712732T3
(es)
*
|
2009-02-17 |
2019-05-14 |
Cornell Res Foundation Inc |
Métodos y kits para el diagnóstico de cáncer y la predicción de valor terapéutico
|
EP2398494A4
(de)
|
2009-02-23 |
2015-10-28 |
Cytomx Therapeutics Inc |
Proproteine und anwendungsverfahren dafür
|
KR101224468B1
(ko)
|
2009-05-20 |
2013-01-23 |
주식회사 파멥신 |
신규한 형태의 이중표적항체 및 그 용도
|
US20120135064A1
(en)
*
|
2009-05-27 |
2012-05-31 |
Northeastern University |
Conjugated nanodelivery vehicles
|
GB0909906D0
(en)
|
2009-06-09 |
2009-07-22 |
Affitech As |
Antibodies
|
US8883832B2
(en)
|
2009-07-06 |
2014-11-11 |
Aerpio Therapeutics Inc. |
Compounds, compositions, and methods for preventing metastasis of cancer cells
|
BRPI1006897A2
(pt)
|
2009-07-06 |
2015-09-08 |
Akebia Therapeutics Inc |
compostos, composições e métodos de prevenção da metástase de células cancerosas.
|
US8956600B2
(en)
*
|
2009-08-10 |
2015-02-17 |
Taiwan Liposome Co. Ltd. |
Ophthalmic drug delivery system containing phospholipid and cholesterol
|
CN102002104A
(zh)
|
2009-08-28 |
2011-04-06 |
江苏先声药物研究有限公司 |
一种抗vegf的单克隆抗体及含有该抗体的药物组合物
|
US8178307B2
(en)
*
|
2009-09-02 |
2012-05-15 |
National Tsing Hua University |
Methods and compositions for detection of lethal cell and uses thereof
|
WO2011028642A1
(en)
|
2009-09-04 |
2011-03-10 |
University Of Louisville Research Foundation, Inc. |
Genetic determinants of prostate cancer risk
|
EP2293071A1
(de)
*
|
2009-09-07 |
2011-03-09 |
Universität Zu Köln |
Biomarker für kolorektalen Krebs
|
IN2012DN01663A
(de)
|
2009-09-16 |
2015-06-05 |
Immunomedics Inc |
|
AU2010306917B2
(en)
|
2009-10-13 |
2014-11-27 |
Rexahn Pharmaceuticals, Inc. |
Polymeric systems for the delivery of anticancer agents
|
EP2488204B1
(de)
|
2009-10-16 |
2016-04-06 |
Oncomed Pharmaceuticals, Inc. |
Therapeutische kombination und verwendungg mit dll4-antagonistische antikörper und mittel gegen bluthochdruck
|
EP2504363B1
(de)
|
2009-11-24 |
2019-05-08 |
Alethia Biotherapeutics Inc. |
Anticlusterin-antikörper und antigenbindende fragmente und ihre verwendung zur reduzierung des tumorvolumens
|
EP3135302A1
(de)
|
2009-12-02 |
2017-03-01 |
Imaginab, Inc. |
J591-minikörper und cys-diakörper zur adressierung des prostataspezifischen membranantigens (psma) und verfahren zu deren verwendung
|
CA2782194C
(en)
|
2009-12-02 |
2018-01-16 |
Immunomedics, Inc. |
Combination of radiolabelled antibodies (rait) and antibody-drug conjugates (adc) for treatment of pancreatic cancer
|
CA2787753A1
(en)
*
|
2010-01-22 |
2011-07-28 |
Immunomedics, Inc. |
Detection of early-stage pancreatic adenocarcinoma
|
UA115517C2
(uk)
*
|
2010-02-08 |
2017-11-27 |
Ейдженсіс, Інк. |
Кон'югат антитіло-лікарський засіб (adc), який зв'язується з білком 161p2f10b
|
GB201002238D0
(en)
|
2010-02-10 |
2010-03-31 |
Affitech As |
Antibodies
|
US9095504B2
(en)
|
2010-03-24 |
2015-08-04 |
Rxi Pharmaceuticals Corporation |
RNA interference in ocular indications
|
EP2550000A4
(de)
|
2010-03-24 |
2014-03-26 |
Advirna Inc |
Selbstfreisetzende rnai-verbindungen von reduzierter grösse
|
TW201138808A
(en)
|
2010-05-03 |
2011-11-16 |
Bristol Myers Squibb Co |
Serum albumin binding molecules
|
EP2796563A1
(de)
|
2010-05-04 |
2014-10-29 |
MedImmune, LLC |
Optimierte Diagnose und Behandlung von Muskelabbauerkrankungen
|
EP3091028A1
(de)
|
2010-05-26 |
2016-11-09 |
Bristol-Myers Squibb Company |
Auf fibronectin basierende gerüstproteine mit erhöhter stabilität
|
BR112012032462A2
(pt)
|
2010-06-25 |
2016-11-08 |
Eisai R&D Man Co Ltd |
agente antitumoral empregando compostos que, em combinação, têm efeito inibidor de quinase.
|
KR102007045B1
(ko)
*
|
2010-07-07 |
2019-08-05 |
티유비아이티에이케이 |
혈관 내피 성장인자 2(vegfr-2/kdr)에 결합하여 그것의 활성을 차단하는 재조합 항체 구조
|
CN101942022B
(zh)
*
|
2010-07-29 |
2013-07-24 |
华东理工大学 |
抗人表皮生长因子受体单链抗体-铁蛋白重链亚基蛋白、构建方法及其用途
|
US8551479B2
(en)
|
2010-09-10 |
2013-10-08 |
Oncomed Pharmaceuticals, Inc. |
Methods for treating melanoma
|
WO2012112443A2
(en)
|
2011-02-15 |
2012-08-23 |
Immunomedics, Inc. |
Anti-mucin antibodies for early detection and treatment of pancreatic cancer
|
US8722044B2
(en)
|
2011-03-15 |
2014-05-13 |
Janssen Biotech, Inc. |
Human tissue factor antibody and uses thereof
|
EP2697394A4
(de)
|
2011-04-12 |
2015-01-14 |
Electronic Biosciences Inc |
Ortsspezifische chemisch modifizierte nanoporenvorrichtungen
|
CN103402519B
(zh)
|
2011-04-18 |
2015-11-25 |
卫材R&D管理有限公司 |
肿瘤治疗剂
|
JO3283B1
(ar)
|
2011-04-26 |
2018-09-16 |
Sanofi Sa |
تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
|
CA2831572C
(en)
|
2011-05-02 |
2019-11-26 |
Immunomedics, Inc. |
Ultrafiltration concentration of allotype selected antibodies for small-volume administration
|
ES2705950T3
(es)
|
2011-06-03 |
2019-03-27 |
Eisai R&D Man Co Ltd |
Biomarcadores para predecir y valorar la capacidad de respuesta de sujetos con cáncer de tiroides y de riñón a compuestos de lenvatinib
|
CA2840143A1
(en)
*
|
2011-06-30 |
2013-01-03 |
Gene Signal International Sa |
Composition comprising inhibitors of irs-1 and of vegf
|
EP2540828A1
(de)
|
2011-06-30 |
2013-01-02 |
Gene Signal International SA |
Zusammensetzung mit Inhibitoren von IRS-1 und VEGF
|
US9682144B2
(en)
|
2011-06-30 |
2017-06-20 |
Gene Signal International, Sa |
Composition comprising inhibitors of IRS-1 and of VEGF
|
US8921533B2
(en)
|
2011-07-25 |
2014-12-30 |
Chromatin Technologies |
Glycosylated valproic acid analogs and uses thereof
|
HUE061002T2
(hu)
|
2011-09-23 |
2023-04-28 |
Mereo Biopharma 5 Inc |
VEGF/DLL4-kötõ ágensek és alkalmazásaik
|
CN102492038B
(zh)
*
|
2011-12-09 |
2014-05-28 |
中国人民解放军军事医学科学院基础医学研究所 |
抗人Tim-3的中和性单克隆抗体L3D及其用途
|
RS61161B1
(sr)
|
2011-12-13 |
2021-01-29 |
Engeneic Molecular Delivery Pty Ltd |
Intaktne minićelije poreklom iz bakterija za isporuku terapijskih agenasa tumorima mozga
|
JP6348848B2
(ja)
|
2012-02-13 |
2018-06-27 |
ガミダ セル リミテッド |
間葉系幹細胞の増殖
|
EP2817028A4
(de)
|
2012-02-22 |
2015-11-04 |
Alethia Biotherapeutics Inc |
Gemeinsame verwendung eines clusterin-inhibitors und eines egfr-inhibitors zur behandlung von krebs
|
WO2013134431A1
(en)
|
2012-03-06 |
2013-09-12 |
Life Technologies Corporation |
Biomarkers for systemic lupus erythematosus
|
EP2830663B1
(de)
|
2012-03-30 |
2019-02-06 |
Sorrento Therapeutics Inc. |
Vollständig humane, an vegfr2 bindende antikörper
|
US20150204873A1
(en)
|
2012-06-18 |
2015-07-23 |
Electonic Biosciences, Inc. |
Cell-free assay device and methods of use
|
US9175266B2
(en)
|
2012-07-23 |
2015-11-03 |
Gamida Cell Ltd. |
Enhancement of natural killer (NK) cell proliferation and activity
|
US9567569B2
(en)
|
2012-07-23 |
2017-02-14 |
Gamida Cell Ltd. |
Methods of culturing and expanding mesenchymal stem cells
|
EP2882757B1
(de)
|
2012-08-07 |
2016-10-05 |
Janssen Pharmaceutica, N.V. |
Verfahren zur herstellung heterocyclischer esterderivate
|
JOP20180012A1
(ar)
|
2012-08-07 |
2019-01-30 |
Janssen Pharmaceutica Nv |
عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
|
US9382329B2
(en)
|
2012-08-14 |
2016-07-05 |
Ibc Pharmaceuticals, Inc. |
Disease therapy by inducing immune response to Trop-2 expressing cells
|
CA2874864C
(en)
|
2012-08-14 |
2023-02-21 |
Ibc Pharmaceuticals, Inc. |
T-cell redirecting bispecific antibodies for treatment of disease
|
JP6371294B2
(ja)
|
2012-10-31 |
2018-08-08 |
オンコメッド ファーマシューティカルズ インコーポレイテッド |
Dll4アンタゴニストによる処置の方法およびモニタリング
|
ES2701076T3
(es)
|
2012-11-24 |
2019-02-20 |
Hangzhou Dac Biotech Co Ltd |
Enlazadores hidrofílicos y sus usos para la conjugación de fármacos a las moléculas que se unen a las células
|
WO2017004144A1
(en)
|
2015-07-01 |
2017-01-05 |
Immunomedics, Inc. |
Antibody-sn-38 immunoconjugates with a cl2a linker
|
HUE057977T2
(hu)
|
2012-12-13 |
2022-06-28 |
Immunomedics Inc |
Ellenanyagok és SN-38 immunkonjugátumainak dózisai javított hatásossággal és csökkentett toxicitással
|
US9334239B2
(en)
|
2012-12-21 |
2016-05-10 |
Eisai R&D Management Co., Ltd. |
Amorphous form of quinoline derivative, and method for producing same
|
JP6526570B2
(ja)
|
2013-01-11 |
2019-06-12 |
マサチューセッツ アイ アンド イヤー インファーマリー |
炎症及び血管形成を減少させるcyp450脂質メタボライト
|
AU2014218318B2
(en)
|
2013-02-18 |
2018-02-15 |
Vegenics Pty Limited |
Ligand binding molecules and uses thereof
|
US20140255413A1
(en)
|
2013-03-07 |
2014-09-11 |
Boehringer Ingelheim International Gmbh |
Combination therapy for neoplasia treatment
|
KR102049990B1
(ko)
|
2013-03-28 |
2019-12-03 |
삼성전자주식회사 |
c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
|
US9452228B2
(en)
|
2013-04-01 |
2016-09-27 |
Immunomedics, Inc. |
Antibodies reactive with an epitope located in the N-terminal region of MUC5AC comprising cysteine-rich subdomain 2 (Cys2)
|
US10274503B2
(en)
|
2013-05-08 |
2019-04-30 |
Vegenics Pty Limited |
Methods of using VEGF-C biomarkers for age-related macular degeneration (AMD) diagnosis
|
CN105264380B
(zh)
|
2013-05-14 |
2017-09-05 |
卫材R&D管理有限公司 |
用于预测和评价子宫内膜癌受试者对乐伐替尼化合物响应性的生物标志
|
KR101541478B1
(ko)
*
|
2013-05-31 |
2015-08-05 |
동아쏘시오홀딩스 주식회사 |
항-vegf 항체 및 이를 포함하는 암 또는 신생혈관형성관련 질환의 예방, 진단 또는 치료용 약학 조성물
|
EP3019243A4
(de)
|
2013-07-12 |
2017-03-15 |
Ophthotech Corporation |
Verfahren zur behandlung oder prävention von augenerkrankungen
|
EP4036118A1
(de)
|
2013-08-01 |
2022-08-03 |
Five Prime Therapeutics, Inc. |
Afucosylierte anti-fgfr2iiib-antikörper
|
US10934550B2
(en)
|
2013-12-02 |
2021-03-02 |
Phio Pharmaceuticals Corp. |
Immunotherapy of cancer
|
US9914769B2
(en)
*
|
2014-07-15 |
2018-03-13 |
Kymab Limited |
Precision medicine for cholesterol treatment
|
MX2016010683A
(es)
|
2014-02-21 |
2017-05-11 |
Ibc Pharmaceuticals Inc |
Terapia para tratar enfermedades mediante la induccion de respuesta inmune de las células que expresan trop-2.
|
US9139649B2
(en)
|
2014-02-25 |
2015-09-22 |
Immunomedics, Inc. |
Humanized anti-CD22 antibody
|
EP3122757B1
(de)
|
2014-02-28 |
2023-09-06 |
Hangzhou Dac Biotech Co., Ltd |
Geladene linker und deren verwendungen zur konjugation
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
IL275497B
(en)
|
2014-03-20 |
2022-09-01 |
Bristol Myers Squibb Co |
Serum proteins with type iii fibronectin binding domains
|
WO2015164541A1
(en)
*
|
2014-04-22 |
2015-10-29 |
Presage Biosciences, Inc. |
Methods and devices for evaluating drug candidates
|
WO2015200260A1
(en)
|
2014-06-24 |
2015-12-30 |
Immunomedics, Inc. |
Anti-histone therapy for vascular necrosis in severe glomerulonephritis
|
US9840553B2
(en)
|
2014-06-28 |
2017-12-12 |
Kodiak Sciences Inc. |
Dual PDGF/VEGF antagonists
|
EP3170005B1
(de)
|
2014-07-18 |
2019-04-10 |
Sanofi |
Verfahren zur vorhersage des ausgangs einer behandlung mit aflibercept bei einem patienten mit verdacht auf ein krebsleiden
|
MX2017001980A
(es)
|
2014-08-28 |
2017-05-04 |
Eisai R&D Man Co Ltd |
Derivado de quinolina muy puro y metodo para su produccion.
|
SI3262071T1
(sl)
|
2014-09-23 |
2020-07-31 |
F. Hoffmann-La Roche Ag |
Način uporabe imunokonjugatov proti CD79b
|
PL3204018T3
(pl)
|
2014-10-07 |
2022-01-03 |
Immunomedics, Inc. |
Neoadiuwantowe zastosowanie koniugatów przeciwciało-lek
|
DK3212233T3
(da)
|
2014-10-31 |
2020-07-27 |
Oncomed Pharm Inc |
Kombinationsterapi til behandling af sygdom
|
TWI695837B
(zh)
|
2014-12-04 |
2020-06-11 |
比利時商健生藥品公司 |
作為激酶調節劑之三唑並嗒
|
WO2016109943A1
(zh)
*
|
2015-01-06 |
2016-07-14 |
珠海亿胜生物制药有限公司 |
抗vegf抗体
|
AR103477A1
(es)
|
2015-01-28 |
2017-05-10 |
Lilly Co Eli |
Compuestos de vegfa / ang2
|
BR112017017428A2
(pt)
|
2015-02-25 |
2018-04-03 |
Eisai R&D Management Co., Ltd. |
?método para supressão do amargor de derivado de quinolina?
|
CN107530291A
(zh)
|
2015-03-03 |
2018-01-02 |
奎尔波特股份有限公司 |
双重负载的脂质体药物制剂
|
EP3265059A4
(de)
|
2015-03-03 |
2018-08-29 |
Cureport Inc. |
Liposomale pharmazeutische kombinationsformulierungen
|
KR20170122809A
(ko)
|
2015-03-04 |
2017-11-06 |
머크 샤프 앤드 돔 코포레이션 |
암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
|
CA2981543A1
(en)
|
2015-04-22 |
2016-10-27 |
Immunomedics, Inc. |
Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
|
KR20180018695A
(ko)
|
2015-06-16 |
2018-02-21 |
가부시키가이샤 프리즘 파마 |
항암제
|
ES2953441T3
(es)
|
2015-06-25 |
2023-11-13 |
Immunomedics Inc |
Combinación de anticuerpos anti-hla-dr o anti-Trop-2 con inhibidores de microtúbulos, inhibidores de parp, inhibidores de la cinasa de bruton o inhibidores de la fosfoinositida 3-cinasa mejora significativamente el resultado terapéutico en el cáncer
|
EP3319936A4
(de)
|
2015-07-12 |
2019-02-06 |
Suzhou M-conj Biotech Co., Ltd. |
Brückenlinker zur konjugation von zellbindenden molekülen
|
US9839687B2
(en)
|
2015-07-15 |
2017-12-12 |
Suzhou M-Conj Biotech Co., Ltd. |
Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
|
SG10201913625XA
(en)
|
2015-08-07 |
2020-03-30 |
Imaginab Inc |
Antigen binding constructs to target molecules
|
CA2999160A1
(en)
|
2015-09-23 |
2017-03-30 |
Oncomed Pharmaceuticals, Inc. |
Methods and compositions for treatment of cancer
|
CN116987187A
(zh)
|
2015-09-23 |
2023-11-03 |
豪夫迈·罗氏有限公司 |
抗-vegf抗体的优化的变体
|
WO2017053617A1
(en)
|
2015-09-23 |
2017-03-30 |
Bristol-Myers Squibb Company |
Fast-off rate serum albumin binding fibronectin type iii domains
|
AU2016343860A1
(en)
*
|
2015-10-30 |
2018-05-10 |
The Jackson Laboratory |
Compositions and methods relating to tumor analysis
|
RU2021107536A
(ru)
|
2015-11-23 |
2021-07-02 |
Файв Прайм Терапьютикс, Инк. |
Ингибиторы fgfr2 отдельно или в комбинации с иммуностимулирующими агентами в лечении рака
|
AU2016364817B2
(en)
|
2015-12-03 |
2020-05-07 |
Regeneron Pharmaceuticals, Inc. |
Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
|
EP3397276A4
(de)
|
2015-12-30 |
2019-12-18 |
Kodiak Sciences Inc. |
Antikörper und konjugate davon
|
JP6910963B2
(ja)
|
2016-01-06 |
2021-07-28 |
株式会社オーダーメードメディカルリサーチ |
高親和性抗vegf抗体
|
CN108779172B
(zh)
*
|
2016-01-06 |
2022-02-08 |
定制药品研究株式会社 |
抑制vegf与nrp1结合的抗体
|
BR112018073133A2
(pt)
*
|
2016-05-10 |
2019-04-30 |
Genentech Inc |
métodos de diminuição das ligações trissulfeto durante a produção recombinante de polipeptídeos
|
EP3467498A4
(de)
*
|
2016-05-30 |
2019-11-13 |
Eiken Kagaku Kabushiki Kaisha |
Monoklonaler anti-human-hämoglobin-antikörper oder antikörperkit, unlöslicher trägerpartikel, an den der monoklonale anti-human-hämoglobin-antikörper immobilisiert ist, und messreagenz und messverfahren mit verwendung davon
|
GB2551979A
(en)
|
2016-06-30 |
2018-01-10 |
Rs Arastirma Egitim Danismanlik Llac Sanayi Ticaret Ltd |
Cleavable polymer drug conjugates
|
US20190204326A1
(en)
*
|
2016-09-27 |
2019-07-04 |
The University Of The Highlands And Islands |
Antigen biomarkers
|
RU2019114205A
(ru)
*
|
2016-10-14 |
2020-11-16 |
Новартис Аг |
Способы лечения глазного заболевания с применением ингибиторов csf-1r
|
US11779604B2
(en)
|
2016-11-03 |
2023-10-10 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses and methods
|
KR20220147721A
(ko)
|
2016-11-14 |
2022-11-03 |
항저우 디에이씨 바이오테크 씨오, 엘티디 |
결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
|
GB2556055B
(en)
|
2016-11-16 |
2022-03-23 |
Rs Arastirma Egitim Danismanlik Ilac Sanayi Ticaret Ltd Sti |
Self-assembled diblock copolymers composed of pegmema and drug bearing polymeric segments
|
US11266745B2
(en)
|
2017-02-08 |
2022-03-08 |
Imaginab, Inc. |
Extension sequences for diabodies
|
EP3606963B1
(de)
|
2017-04-03 |
2023-08-30 |
F. Hoffmann-La Roche AG |
An steap-1 bindende antikörper
|
BR112019022643A2
(pt)
|
2017-05-02 |
2020-05-19 |
Nat Cancer Center Japan |
conjugado de fármaco-anticorpo anti-fibrina insolúvel clivável por plasmina
|
SG10202112636SA
(en)
|
2017-05-16 |
2021-12-30 |
Five Prime Therapeutics Inc |
Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment
|
US10543231B2
(en)
|
2017-05-19 |
2020-01-28 |
Mayo Foundation For Medical Education And Research |
Methods and materials for treating cancer
|
US10894019B2
(en)
|
2017-08-15 |
2021-01-19 |
University Of South Carolina |
Drug delivery system and method for targeting cancer stem cells
|
JP7436365B2
(ja)
*
|
2017-12-29 |
2024-02-21 |
エフ. ホフマン-ラ ロシュ アーゲー |
抗vegf抗体及び使用の方法
|
CN112055718A
(zh)
*
|
2018-03-19 |
2020-12-08 |
药物抗体公司 |
抗vegfr-2抗体
|
WO2019211492A1
(en)
|
2018-05-04 |
2019-11-07 |
Tollys |
Tlr3 ligands that activate both epithelial and myeloid cells
|
US11672767B2
(en)
|
2019-05-13 |
2023-06-13 |
University Of South Carolina |
Enzymatically cleavable self-assembled nanoparticles for morphogen delivery
|
EP4021894A1
(de)
|
2019-08-30 |
2022-07-06 |
University of Rochester |
Septininhibitoren zur behandlung von krebs
|
EP4041312A4
(de)
|
2019-10-10 |
2023-12-20 |
Kodiak Sciences Inc. |
Verfahren zur behandlung einer augenstörung
|
TW202138388A
(zh)
|
2019-12-30 |
2021-10-16 |
美商西根公司 |
以非海藻糖苷化抗-cd70抗體治療癌症之方法
|
US11883432B2
(en)
|
2020-12-18 |
2024-01-30 |
Century Therapeutics, Inc. |
Chimeric antigen receptor system with adaptable receptor specificity
|
JPWO2022239720A1
(de)
|
2021-05-10 |
2022-11-17 |
|
|